cardiovascular medicine
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Participants aged between 30 and 85 years, regardless of gender, who meet the diagnostic criteria for ischemic cardiomyopathy (ICM) complicated by heart failure (HF) as defined in the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024, will be eligible for inclusion. Additionally, participants must have a confirmed diagnosis of urolithiasis based on imaging (ultrasound or CT), a cardiac function classification of NYHA class II to IV, stable vital signs including blood pressure and heart rate, and the ability to tolerate oral medication. All participants must provide written informed consent before enrollment in the study.
Exclusion criteria
Exclusion criteria: Exclusion criteria include: having undergone surgical intervention or extracorporeal shock wave lithotripsy (ESWL) for urolithiasis within the past three months; presence of other severe organic heart diseases (e.g., hypertrophic cardiomyopathy, valvular heart disease); significant hepatic or renal dysfunction (e.g., ALT or AST > 3 times the upper limit of normal, serum creatinine > 265 µmol/L); concurrent active infections, malignancies, or autoimmune diseases; participation in other clinical drug trials within the past month; known allergy to Lysimachia christinae or any components of the quadruple-drug regimen; pregnancy, lactation, or plans to become pregnant; and any other condition deemed unsuitable for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac Function Parameters;urinary stone expulsion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory factors;renal function; | — |
Countries
China
Contacts
Guidong People’s Hospital of Guangxi Zhuang Autonomous Region